The tumor microenvironment state associates with response to HPV therapeutic vaccination in patients with respiratory papillomatosis
Science Translational Medicine · 25.10.2023 · 15 (719)
DOI: 10.1126/scitranslmed.adj0740 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Translational Medicine, erschienen am 25.10.2023. Verfasst von Scott M Norberg und 14 weiteren Autor:innen. Beteiligte Einrichtung: Center for Immune-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA. Hauptthemen laut MEDLINE: Papillomavirus Infections, Respiratory Tract Infections, Papilloma. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDCD NIH HHS, Intramural NIH HHS.
Abstract (Originalsprache)
Recurrent respiratory papillomatosis (RRP) is a rare, debilitating neoplastic disorder caused by chronic infection with human papillomavirus (HPV) type 6 or 11 and characterized by growth of papillomas in the upper aerodigestive tract. There is no approved medical therapy, and patients require repeated debulking procedures to maintain voice and airway function. PRGN-2012 is a gorilla adenovirus immune-therapeutic capable of enhancing HPV 6/11–specific T cell immunity. This first-in-human, phase 1 study (NCT04724980) of adjuvant PRGN-2012 treatment in adult patients with severe, aggressive RRP demonstrates the overall safety and clinically meaningful benefit observed with PRGN-2012, with a 50% complete response rate in patients treated at the highest dose. Responders demonstrate greater expansion of peripheral HPV-specific T cells compared with nonresponders. Additional correlative studies identify an association between reduced baseline papilloma HPV gene expression, greater interferon responses and expression of CXCL9 and CXCL10 , and greater papilloma T cell infiltration in responders. Conversely, nonresponders were characterized by greater HPV and CXCL8 gene expression, increased neutrophilic cell infiltration, and reduced T cell papilloma infiltration. These results suggest that papilloma HPV gene expression may regulate interferon signaling and chemokine expression profiles within the tumor microenvironment that cooperate to govern clinical response to therapeutic HPV vaccination in patients with respiratory papillomatosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Center for Immune-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
- Surgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
- Precigen Inc., Germantown, MD 20876, USA.
ORCID-Profile: Scott M Norberg, Cem Sievers, Yvette Robbins, Xinping Yang, Elizabeth Ward, Jeffrey Schlom, James Gulley, Amy Lankford, Roshanak Semnani, Clint T Allen
Förderung
- NIDCD NIH HHS
- Intramural NIH HHS
Zitieren
APA
Norberg, S. M., Bai, K., Sievers, C., Robbins, Y., Friedman, J., Yang, X., Kenyon, M., Ward, E., Schlom, J., Gulley, J., Lankford, A., Semnani, R., Sabzevari, H., Brough, D. E., & Allen, C. T. (2023). The tumor microenvironment state associates with response to HPV therapeutic vaccination in patients with respiratory papillomatosis. Science Translational Medicine, 15(719). https://doi.org/10.1126/scitranslmed.adj0740
Vancouver
Norberg SM, Bai K, Sievers C, Robbins Y, Friedman J, Yang X, et al. The tumor microenvironment state associates with response to HPV therapeutic vaccination in patients with respiratory papillomatosis. Science Translational Medicine. 2023;15(719). doi:10.1126/scitranslmed.adj0740
BibTeX
@article{Norberg2023,
author = {Norberg, Scott M and Bai, Ke and Sievers, Cem and Robbins, Yvette and Friedman, Jay and Yang, Xinping and Kenyon, Meg and Ward, Elizabeth and Schlom, Jeffrey and Gulley, James and Lankford, Amy and Semnani, Roshanak and Sabzevari, Helen and Brough, Douglas E and Allen, Clint T},
title = {The tumor microenvironment state associates with response to HPV therapeutic vaccination in patients with respiratory papillomatosis},
journal = {Science Translational Medicine},
year = {2023},
volume = {15},
number = {719},
doi = {10.1126/scitranslmed.adj0740}
}
EUVIMED